Sep 08, 2021 06:31 PM (GMT+8) · EqualOcean
Cailian, September 8 (Xinhua) - Nanjing hi tech announced that it had previously disclosed that the company was publicly listed in Nanjing public resources trading center to transfer 51% of its holding subsidiary CHENGONG pharmaceutical. On August 30, 2021, the company received the letter on registration of intended transferee of property right transfer project from Nanjing public resources trading center. During the period of public listing, an intended transferee of Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin pharmaceutical") came to register. After review, Nanjing Public Resources Trading Center accepted its registration, The company has confirmed the qualification of its intended transferee. On September 7, 2021, the company and Hanxin pharmaceutical signed the property right transaction contract under the authentication of Nanjing public resources trading center. The final transaction price of 51% equity of CHENGONG pharmaceutical is RMB 183 million.